Celldex Therapeutics has successfully completed patient enrollment for its two global Phase III clinical studies—Embarq-Csu1 and Embarq-Csu2—of the innovative drug Barzolvolimab for chronic spontaneous urticaria.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
This significant progress marks a solid step forward for the therapy in the critical phase of validating its efficacy and safety, laying a strong foundation for subsequent data analysis and regulatory submissions.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
US Job Growth Revised Downward, Signs of Cooling Labor Market More Apparent
Cointime•2026/08/28 14:15
Market Pricing Indicates 50% Probability of Fed Rate Hike in September
Cointime•2026/08/28 14:15
US Employment Growth Revised Downward, Signs of Labor Market Cooling More Apparent
Cointime•2026/08/28 14:15
Crypto prices
More
Bitcoin
BTC
$78,618.32
-1.01%
Ethereum
ETH
$2,476.67
-0.61%
Tether USDt
USDT
$1.0000
+0.01%
BNB
BNB
$699.93
-0.96%
XRP
XRP
$1.4
-3.32%
USDC
USDC
$0.9999
-0.00%
Solana
SOL
$103.98
-1.41%
TRON
TRX
$0.3404
+0.70%
Hyperliquid
HYPE
$82.74
+0.46%
Dogecoin
DOGE
$0.08599
-2.35%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now